Criteri di appropriatezza nel trattamento della fibrillazione atriale con dronedarone: Aspetti pratici. L'Opinione di un gruppo di esperti cardiologi Italiani

Translated title of the contribution: Criteria of appropriateness in the treatment of atrial fibrillation with dronedarone: Practical aspects. The opinion of a group of Italian expert cardiologists

Giovanni Luca Botto, Alessandro Capucci, Antonio Raviele, Giuseppe Boriani, Michele Brignole, Leonardo Calò, Valeria Calvi, Roberto De Ponti, Antonio De Simone, Pietro Delise, Matteo Di Biase, Federico Lombardi, Maurizio Lunati, Maurizio Santomauro, Michele Senni, Giuseppe Stabile, Sakis Themistoclakis, Massimo Tritto, Massimo Volpe

Research output: Contribution to journalArticle

Abstract

Antiarrhythmic agents are among the therapeutic options available for the treatment of atrial fibrillation when a rhythm control strategy is required. Although their efficacy seems to be generally comparable to that of non-pharmacological interventions, the use of these agents remains controversial. In particular, among this class of drugs, the use of dronedarone in clinical practice is a matter of debate. In this paper, the authors aimed to address these issues, involving a team of expert cardiologists who discussed about the potential use of dronedarone in different clinical scenarios. The RAND/UCLA appropriateness method was used to develop appropriateness measures for the optimal management of patients treated with dronedarone, by combining the best available scientific evidence with the collective judgment of experts. To this purpose, a group of experts was identified and asked to rate the benefit-to-harm ratio of 52 clinical scenarios. Each indication was classified as "appropriate", "uncertain" or "inappropriate" in accordance with the panelists' median score. The classification of each scenario has led to the development of several recommendations for clinical practice. The use of dronedarone for the management of paroxysmal and persistent atrial fibrillation has evolved over time: this antiarrhythmic drug appears to be useful not only in monitoring symptoms, but also in reducing hospitalization and mortality rates in patients with atrial fibrillation.

Original languageItalian
Pages (from-to)773-783
Number of pages11
JournalGiornale Italiano di Cardiologia
Volume14
Issue number11
Publication statusPublished - Nov 2013

Fingerprint

Atrial Fibrillation
Anti-Arrhythmia Agents
Therapeutics
Hospitalization
Mortality
Cardiologists
dronedarone
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Criteri di appropriatezza nel trattamento della fibrillazione atriale con dronedarone : Aspetti pratici. L'Opinione di un gruppo di esperti cardiologi Italiani. / Botto, Giovanni Luca; Capucci, Alessandro; Raviele, Antonio; Boriani, Giuseppe; Brignole, Michele; Calò, Leonardo; Calvi, Valeria; De Ponti, Roberto; De Simone, Antonio; Delise, Pietro; Di Biase, Matteo; Lombardi, Federico; Lunati, Maurizio; Santomauro, Maurizio; Senni, Michele; Stabile, Giuseppe; Themistoclakis, Sakis; Tritto, Massimo; Volpe, Massimo.

In: Giornale Italiano di Cardiologia, Vol. 14, No. 11, 11.2013, p. 773-783.

Research output: Contribution to journalArticle

Botto, GL, Capucci, A, Raviele, A, Boriani, G, Brignole, M, Calò, L, Calvi, V, De Ponti, R, De Simone, A, Delise, P, Di Biase, M, Lombardi, F, Lunati, M, Santomauro, M, Senni, M, Stabile, G, Themistoclakis, S, Tritto, M & Volpe, M 2013, 'Criteri di appropriatezza nel trattamento della fibrillazione atriale con dronedarone: Aspetti pratici. L'Opinione di un gruppo di esperti cardiologi Italiani', Giornale Italiano di Cardiologia, vol. 14, no. 11, pp. 773-783.
Botto, Giovanni Luca ; Capucci, Alessandro ; Raviele, Antonio ; Boriani, Giuseppe ; Brignole, Michele ; Calò, Leonardo ; Calvi, Valeria ; De Ponti, Roberto ; De Simone, Antonio ; Delise, Pietro ; Di Biase, Matteo ; Lombardi, Federico ; Lunati, Maurizio ; Santomauro, Maurizio ; Senni, Michele ; Stabile, Giuseppe ; Themistoclakis, Sakis ; Tritto, Massimo ; Volpe, Massimo. / Criteri di appropriatezza nel trattamento della fibrillazione atriale con dronedarone : Aspetti pratici. L'Opinione di un gruppo di esperti cardiologi Italiani. In: Giornale Italiano di Cardiologia. 2013 ; Vol. 14, No. 11. pp. 773-783.
@article{4881dd6d939a4e02a8874c0a59cf2291,
title = "Criteri di appropriatezza nel trattamento della fibrillazione atriale con dronedarone: Aspetti pratici. L'Opinione di un gruppo di esperti cardiologi Italiani",
abstract = "Antiarrhythmic agents are among the therapeutic options available for the treatment of atrial fibrillation when a rhythm control strategy is required. Although their efficacy seems to be generally comparable to that of non-pharmacological interventions, the use of these agents remains controversial. In particular, among this class of drugs, the use of dronedarone in clinical practice is a matter of debate. In this paper, the authors aimed to address these issues, involving a team of expert cardiologists who discussed about the potential use of dronedarone in different clinical scenarios. The RAND/UCLA appropriateness method was used to develop appropriateness measures for the optimal management of patients treated with dronedarone, by combining the best available scientific evidence with the collective judgment of experts. To this purpose, a group of experts was identified and asked to rate the benefit-to-harm ratio of 52 clinical scenarios. Each indication was classified as {"}appropriate{"}, {"}uncertain{"} or {"}inappropriate{"} in accordance with the panelists' median score. The classification of each scenario has led to the development of several recommendations for clinical practice. The use of dronedarone for the management of paroxysmal and persistent atrial fibrillation has evolved over time: this antiarrhythmic drug appears to be useful not only in monitoring symptoms, but also in reducing hospitalization and mortality rates in patients with atrial fibrillation.",
keywords = "Appropriateness, Atrial fibrillation, Dronedarone",
author = "Botto, {Giovanni Luca} and Alessandro Capucci and Antonio Raviele and Giuseppe Boriani and Michele Brignole and Leonardo Cal{\`o} and Valeria Calvi and {De Ponti}, Roberto and {De Simone}, Antonio and Pietro Delise and {Di Biase}, Matteo and Federico Lombardi and Maurizio Lunati and Maurizio Santomauro and Michele Senni and Giuseppe Stabile and Sakis Themistoclakis and Massimo Tritto and Massimo Volpe",
year = "2013",
month = "11",
language = "Italian",
volume = "14",
pages = "773--783",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "11",

}

TY - JOUR

T1 - Criteri di appropriatezza nel trattamento della fibrillazione atriale con dronedarone

T2 - Aspetti pratici. L'Opinione di un gruppo di esperti cardiologi Italiani

AU - Botto, Giovanni Luca

AU - Capucci, Alessandro

AU - Raviele, Antonio

AU - Boriani, Giuseppe

AU - Brignole, Michele

AU - Calò, Leonardo

AU - Calvi, Valeria

AU - De Ponti, Roberto

AU - De Simone, Antonio

AU - Delise, Pietro

AU - Di Biase, Matteo

AU - Lombardi, Federico

AU - Lunati, Maurizio

AU - Santomauro, Maurizio

AU - Senni, Michele

AU - Stabile, Giuseppe

AU - Themistoclakis, Sakis

AU - Tritto, Massimo

AU - Volpe, Massimo

PY - 2013/11

Y1 - 2013/11

N2 - Antiarrhythmic agents are among the therapeutic options available for the treatment of atrial fibrillation when a rhythm control strategy is required. Although their efficacy seems to be generally comparable to that of non-pharmacological interventions, the use of these agents remains controversial. In particular, among this class of drugs, the use of dronedarone in clinical practice is a matter of debate. In this paper, the authors aimed to address these issues, involving a team of expert cardiologists who discussed about the potential use of dronedarone in different clinical scenarios. The RAND/UCLA appropriateness method was used to develop appropriateness measures for the optimal management of patients treated with dronedarone, by combining the best available scientific evidence with the collective judgment of experts. To this purpose, a group of experts was identified and asked to rate the benefit-to-harm ratio of 52 clinical scenarios. Each indication was classified as "appropriate", "uncertain" or "inappropriate" in accordance with the panelists' median score. The classification of each scenario has led to the development of several recommendations for clinical practice. The use of dronedarone for the management of paroxysmal and persistent atrial fibrillation has evolved over time: this antiarrhythmic drug appears to be useful not only in monitoring symptoms, but also in reducing hospitalization and mortality rates in patients with atrial fibrillation.

AB - Antiarrhythmic agents are among the therapeutic options available for the treatment of atrial fibrillation when a rhythm control strategy is required. Although their efficacy seems to be generally comparable to that of non-pharmacological interventions, the use of these agents remains controversial. In particular, among this class of drugs, the use of dronedarone in clinical practice is a matter of debate. In this paper, the authors aimed to address these issues, involving a team of expert cardiologists who discussed about the potential use of dronedarone in different clinical scenarios. The RAND/UCLA appropriateness method was used to develop appropriateness measures for the optimal management of patients treated with dronedarone, by combining the best available scientific evidence with the collective judgment of experts. To this purpose, a group of experts was identified and asked to rate the benefit-to-harm ratio of 52 clinical scenarios. Each indication was classified as "appropriate", "uncertain" or "inappropriate" in accordance with the panelists' median score. The classification of each scenario has led to the development of several recommendations for clinical practice. The use of dronedarone for the management of paroxysmal and persistent atrial fibrillation has evolved over time: this antiarrhythmic drug appears to be useful not only in monitoring symptoms, but also in reducing hospitalization and mortality rates in patients with atrial fibrillation.

KW - Appropriateness

KW - Atrial fibrillation

KW - Dronedarone

UR - http://www.scopus.com/inward/record.url?scp=84890259329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890259329&partnerID=8YFLogxK

M3 - Articolo

C2 - 24326640

AN - SCOPUS:84890259329

VL - 14

SP - 773

EP - 783

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 11

ER -